# reload+after+2024-01-19 22:46:35.039934
address1§321 Harrison Avenue
address2§8th Floor
city§Boston
state§MA
zip§02118
country§United States
phone§781 797 0979
website§https://pepgen.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD). The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is headquartered in Boston, Massachusetts.
fullTimeEmployees§63
companyOfficers§[{'maxAge': 1, 'name': 'Dr. James G. McArthur Ph.D.', 'age': 61, 'title': 'President, CEO, Treasurer, Secretary & Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 834983, 'exercisedValue': 0, 'unexercisedValue': 2396032}, {'maxAge': 1, 'name': 'Mr. Noel P. Donnelly M.B.A.', 'age': 53, 'title': 'Chief Financial Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 650170, 'exercisedValue': 0, 'unexercisedValue': 147672}, {'maxAge': 1, 'name': 'Mr. Niels  Svenstrup Ph.D.', 'age': 53, 'title': 'Senior Vice President of Chemistry, Manufacturing & Control', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 455150, 'exercisedValue': 0, 'unexercisedValue': 168610}, {'maxAge': 1, 'name': 'Dr. Michael  Gait Ph.D.', 'title': 'Founder & Scientific Advisory Board Member', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jaya  Goyal Ph.D.', 'age': 55, 'title': 'Executive Vice President of Research & Preclinical Development', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 558396, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michelle L. Mellion M.D.', 'age': 47, 'title': 'Senior VP & Head of Clinical Development', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kyle  Breidenstine', 'title': 'VP of Finance & Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§6
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
currency§USD
dateShortInterest§1702598400
forwardEps§-3.66
exchange§NMS
quoteType§EQUITY
shortName§PepGen Inc.
longName§PepGen Inc.
firstTradeDateEpochUtc§1651843800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d8556119-2e86-3dba-8e6a-e25559b6dab2
gmtOffSetMilliseconds§-18000000
targetHighPrice§26.0
targetLowPrice§21.0
targetMeanPrice§22.8
targetMedianPrice§22.0
recommendationMean§1.2
recommendationKey§strong_buy
numberOfAnalystOpinions§5
quickRatio§6.182
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
